The ZEPHyR study: A randomized comparison of linezolid and vancomycin for MRSA pneumonia

Medecine et Maladies Infectieuses

Volumn 43, Issue 11-12, 2013, Pages 451-455

  Chavanet, P ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Linezolid; MRSA; Nosocomial pneumonia; Randomized study; Vancomycin

Indexed keywords

AZTREONAM; LINEZOLID; VANCOMYCIN;

ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; HOSPITAL INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL (TOPIC); PROCESS OPTIMIZATION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ÉTUDE RANDOMISÉE; LINEZOLID; LINÉZOLIDE; MRSA; NOSOCOMIAL PNEUMONIA; PNEUMONIE NOSOCOMIALE; RANDOMIZED STUDY; SARM; VANCOMYCIN; VANCOMYCINE;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DOUBLE-BLIND METHOD; HUMANS; KIDNEY DISEASES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84889686121     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.09.011     Document Type: Article

References (23)

1. Thiolet J.M., Vaux S., Lamy M., Gautier A., Barret A.S., Léon L. Enquête nationale de prévalence des infections nosocomiales et des traitements antiinfectieux en établissements de santé 2012, [Résultats. Disponible sur: www.invs.sante.fr].
2. Kollef M.H., Shorr A., Tabak Y.P., Gupta V., Liu L.Z., Johannes R.S. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
3. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S.aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
4. Welte T., Pletz M.W. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 2010, 36:391-400.
5. Han J.H., Mascitti K.B., Edelstein P.H., Bilker W.B., Lautenbach E. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2012, 56(10):5164-5170.
6. Wunderink R.G., Niederman M.S., Kollef M.H., Shorr A.F., Kunkel M.J., Baruch A., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
7. Rubinstein E., Cammarata S., Oliphant T., Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001, 32:402-412.
8. Wunderink R.G., Cammarata S.K., Oliphant T.H., Kollef M.H. Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003, 25:980-992.
9. Kollef M.H., Rello J., Cammarata S.K., Croos-Dabrera R.V., Wunderink R.G. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004, 30:388-394.
10. Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45(9):2460-2467.
11. Roberts J.A., Taccone F.S., Udy A.A., Vincent J.L., Jacobs F., Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011, 55(6):2704-2709.
12. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., Kollef M.H. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
13. Scheetz M.H., Wunderink R.G., Postelnick M.J., Noskin G.A. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006, 26:539-550.
14. Cruciani M., Gatti G., Lazzarini L., Furlan G., Broccali G., Malena M., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996, 38:865-869.
15. Georges H., Leroy O., Alfandari S., Guery B., Roussel-Delvallez M., Dhennain C., et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997, 16:385-388.
16. Conte J.E., Golden J.A., Kipps J., Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002, 46:1475-1480.
17. Boselli E., Breilh D., Rimmelé T., Djabarouti S., Toutain J., Chassard D., et al. Pharmacokinetics and intrapulmonary concentrations of linezolide administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005, 33:1529-1533.
18. Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998, 113:412-420.
19. Rello J. Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. Eur Respir Rev 2007, 16:33-39.
20. Kim S.H., Park W.B., Lee K.D., Kang C.I., Kim H.B., Oh M.D., et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis 2003, 37:794-799.
21. Gasch O., Camoez M., Domínguez M.A., Padilla B., Pintado V., Almirante B., et al. Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2013, 68:1423-1430.
22. González C., Rubio M., Romero-Vivas J., González M., Picazo J.J. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999, 29:1171-1177.
23. van Hal S.J., Lodise T.P., Paterson D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012, 54:755-771.